See the latest news and media coverage for BIOGEN Científica. We track all announcements, press releases, and industry mentions in real time, all in one place.
Last updated
In short: BIOGEN Científica advanced its clinical pipeline, securing a licensing deal with Alteogen and reporting positive data in lupus and SMA treatments.
Biogen's lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...
BIIB080 / CELIA: Biogen's tau ASO BIIB080 (CELIA) is an 18-month proof-of-concept test of intracellular tau lowering — phase 1b showed ~60% CSF tau knockdown...
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Biogen (BIIB) has put fresh attention on its...
Track BIOGEN Científica and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.